Product information and disease descriptionPlace of product in therapyDisease description
Long-term morbidity
13 evidence topics · 14 sources
Metastatic uveal melanoma as the leading cause of death
“The audited cause of death was uveal melanoma in 145 (61%) of them.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Metastatic uveal melanoma was the leading single cause of death throughout the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Disability attributed to the condition: vision impairment, enucleation, pain, and organ failure
Metastatic sites at death, COMS large tumor trial
“A total of 269 patients (62%) had histopathologically confirmed melanoma metastasis at the time of death, and metastasis was suspected in 92 additional patients (21%) on the basis of imaging and tests but without tissue confirmation. The common sites were liver (93%), lung (24%), and bone (16%); multiple sites were identified in 87% of patients with metastasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic and extrahepatic metastatic sites during follow-up
“Liver was the most common site (89%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Survival after symptomatic brain metastases
Primary tumor treatment: surgery and radiation trends, 1975 to 2020
“The previously reported declining trend in the number of patients treated with surgery alone (93% from 1975 to 1977 vs. 21% from 2017 to 2020) ensued, with ongoing corresponding increasing rates of radiation as the primary treatment (1% from 1975 to 1977 vs. 58% from 2017 to 2020).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Enucleation of the affected eye
Radiation-related ocular complications: maculopathy, optic neuropathy, neovascular glaucoma, and cataract
“Any type of RT can lead to posterior complications such as maculopathy, optic neuropathy, neovascular glaucoma and retinopathy, which can have an impact on vision and eye preservation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the anterior segment of the eye, cataract and dry eye are the most common side-effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Signs of RT-induced maculopathy on fundus examination are detected in ≤66.5% of cases within 3 years of PBR.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity after iodine-125 brachytherapy, COMS medium tumor trial
“Three years after I(125) brachytherapy, median visual acuity was 20/125, with 34% having 20/40 or better and 45% having 20/200 or worse visual acuity, including eyes that were enucleated within 3 years of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychological morbidity: anxiety, depression, and worry about recurrence after prognostic testing
“Compared to other groups, survivors with poor prognoses showed initially elevated anxiety and depression and consistently elevated worry about local or distant recurrence over 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) HADS anxiety score at baseline (7.4 [4.0]) was higher than at 3 months (5.4 [3.7]; P < .001) or 12 months (4.7 [3.4]; P < .001), and decreased with older age (coefficient estimate [SD], -0.06 [0.02]; P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychological burden of surveillance and of eye loss
“The discussion should include the emotional and organisational impact of this surveillance strategy as well as its frequency and duration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“QoL is affected by specific concerns, including recurrence and loss of the eye or visual impairment. These need to be considered by ophthalmologists and oncologists, who should provide appropriate care, including psychological support, as depressive symptoms are common after ocular tumour treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote